Embodiments herein relate to biofouling resistant coatings for medical devices. In an embodiment, an anti-fouling coated medical device is included having a substrate and a coating disposed over the substrate. The coating can include a hydrogel, and a polyzwitterion. The polyzwitterion can include a bound portion and an unbound portion. In some embodiments the coating can further include a heparin compound. Other embodiments are also included herein.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

A supramolecular polymer blend includes a thermoplastic elastomer functionalized with at least one bis-urea moiety and a functional component which is functionalized with at least one bis-urea moiety which is present in an amount of 0.5-40 wt % based on the total mass of the polymer blend. The functional component is selected from polyalkylene glycol, betaine, polysaccharide, zwitterion, polyol or taurine and derivatives thereof. Implants including the polymer blend and a process to manufacture the implants are also provided.

The present invention provides a medical material and a blood purification apparatus each having high anti-thrombotic properties and high safety. The apparatus is produced by incorporating therein a medical material which has a hydrophilic copolymerization polymer present on a surface thereof which is to be in contact with blood, wherein particulate protuberances each having a particle diameter of 50 nm or more are present on the surface which is to be in contact with blood at a density of 3 particles/?m.sup.2 or less and the relaxation time of adsorbed water in the hydrophilic copolymerization polymer is 2.5?10.sup.?8 seconds or shorter and 5.0?10.sup.?10 seconds or longer at ?40? C.

The present invention provides a medical material and a blood purification apparatus each having high anti-thrombotic properties and high safety. The apparatus is produced by incorporating therein a medical material which has a hydrophilic copolymerization polymer present on a surface thereof which is to be in contact with blood, wherein particulate protuberances each having a particle diameter of 50 nm or more are present on the surface which is to be in contact with blood at a density of 3 particles/?m.sup.2 or less and the relaxation time of adsorbed water in the hydrophilic copolymerization polymer is 2.5?10.sup.?8 seconds or shorter and 5.0?10.sup.?10 seconds or longer at ?40? C.

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.